PMID- 23972707
OWN - NLM
STAT- MEDLINE
DCOM- 20131029
LR  - 20211203
IS  - 1532-8708 (Electronic)
IS  - 0093-7754 (Linking)
VI  - 40
IP  - 4
DP  - 2013 Aug
TI  - Systemic treatment options for untreated patients with metastatic clear cell 
      renal cancer.
PG  - 436-43
LID - S0093-7754(13)00088-2 [pii]
LID - 10.1053/j.seminoncol.2013.05.013 [doi]
AB  - The introduction of therapy targeting vascular endothelial growth factor (VEGF) 
      and the mammalian target of rapomycin (mTOR) has significantly improved the 
      outcome of patients with metastatic renal cancer. In this article a comprehensive 
      overview of treatment choices for previously untreated patients with metastatic 
      disease is given. Both established and emerging therapeutic options are 
      discussed, as are prognostic factors predicting outcome.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Molina, Ana M
AU  - Molina AM
AD  - Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of 
      Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. 
      molinaa@mskcc.org
FAU - Motzer, Robert J
AU  - Motzer RJ
FAU - Heng, Daniel Y
AU  - Heng DY
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Oncol
JT  - Seminars in oncology
JID - 0420432
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Indazoles)
RN  - 0 (Indoles)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 0 (Pyrroles)
RN  - 0 (Sulfonamides)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 624KN6GM2T (temsirolimus)
RN  - 7RN5DR86CK (pazopanib)
RN  - V99T50803M (Sunitinib)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Bevacizumab
MH  - Carcinoma, Renal Cell/*drug therapy/secondary
MH  - Humans
MH  - Indazoles
MH  - Indoles/adverse effects/therapeutic use
MH  - Kidney Neoplasms/*drug therapy/pathology
MH  - Prognosis
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Pyrimidines/therapeutic use
MH  - Pyrroles/adverse effects/therapeutic use
MH  - Sirolimus/analogs & derivatives/therapeutic use
MH  - Sulfonamides/therapeutic use
MH  - Sunitinib
EDAT- 2013/08/27 06:00
MHDA- 2013/10/30 06:00
CRDT- 2013/08/27 06:00
PHST- 2013/08/27 06:00 [entrez]
PHST- 2013/08/27 06:00 [pubmed]
PHST- 2013/10/30 06:00 [medline]
AID - S0093-7754(13)00088-2 [pii]
AID - 10.1053/j.seminoncol.2013.05.013 [doi]
PST - ppublish
SO  - Semin Oncol. 2013 Aug;40(4):436-43. doi: 10.1053/j.seminoncol.2013.05.013.